Welcome to

Our Event

Over the past several years, cancer immunotherapy has made extraordinary progress both conceptually and in clinical practice. The recent FDA approval of drugs in this area has paved the way for many upcoming independent and combination therapies in the immuno-oncology segment.

A variety of strategies are continuing to evolve in the laboratory and in the clinic, including cancer vaccines, T cells, and immune checkpoint blockade. Despite their promise, much more research is needed to understand how and why certain cancers fail to respond to immunotherapy and to predict which therapeutic strategies, or combinations thereof, are most appropriate for each patient.

The Cancer Immunotherapy Congress held on 19 - 20 May 2016 in Boston, USA presented these ongoing challenges along with some recent technological advances.

Key sessions:

• Cellular Immunotherapy
• Predictive Biomarkers for response
• Combinational Therapy and Toxicity
• New Immunotherapy Targets
• Pre-clinical & Translational
• Moving Beyond Current Vaccines

Key Speakers:

  • James B. Trager
    Vice President, Research
    Dendreon Pharmaceuticals, Inc,
    Seattle, USA
  • Jeffrey H. Hanke
    Executive Vice President, Research and Development, and CSO TESARO,
    Massachusetts, USA
  • Dr. Scott Cameron
    Senior Director and Clinical Program Leader
    Novartis Oncology Translational Research,
    Boston, USA
  • Kuldeep Neote
    Senior Director, New Ventures
    Johnson & Johnson Innovation, 
    California, USA
  • James Gulley
    Chief, Genitourinary Malignancies Branch
    Director, Medical Oncology Service, Center for Cancer Research
    NCI, NIH, Washington, USA
  • Michael Briskin 
    Vice President, Discovery research
    Jounce Therapeutics,
    Cambridge, USA

Awesome Image




0 Hours of Networking


Full Name *
Email Id *

Company *
Job Title *

Country Code *
Phone Number *

Country *


Our Speakers

Dr. Aaron Foster
Dr. Aaron Foster

Senior Director Cellular Biology & Immunology, Bellicum Pharmaceuticals, Texas, USA

Dr. Ashwani Sood
Dr. Ashwani Sood

Assistant Member, Department of Immunology Roswell Park Cancer Institute, New York

Dr. Carol O'Hear
Dr. Carol O'Hear

Asst Medical Director, Cancer Immunotherapy, Genentech, San Fransisco

Dr. Elaine Pinheiro
Dr. Elaine Pinheiro

Principal Scientist & Pre - Clinical Lead Pembrolizumab (Keytruda) Program, IMR Early Discovery, Merck Research Laboratories, Boston

Dr. Eunice Lee
Dr. Eunice Lee

Branch Chief, Division of Molecular Genetics and Pathology of the Office of In Vitro Diagnostics and Radiological Health CDRH, FDA, Maryland

Dr. Hye-Jung Kim
Dr. Hye-Jung Kim

Senior scientist Dana-Farber Cancer Institute, Boston, USA

Dr. James B. Trager
Dr. James B. Trager

Vice President, Research Dendreon Pharmaceuticals, Inc, Seattle, USA

Dr. James Gulley
Dr. James Gulley

M.D., Ph.D., F.A.C.P. Chief, Genitourinary Malignancies Branch Director, Medical Oncology Service Center for Cancer Research, NCI, NIH, Washington, USA

Know All Speakers

Event Sponsors





Sponsors & Exhibitors

Official Logistics Partner

Become Sponsor Know All Sponsors

Media Partners

Supporting Association

Submit your Poster Presentation


The Cancer Immunotherapy Congress

Four Points Sheraton Wakefield Boston
1 Audubon Road

For directions, click here

Our block of rooms at the Four Points Sheraton Wakefield Boston has now expired. You may still be able to book accommodation at the Four Points Sheraton Wakefield Boston by visiting their website directly - http://www.starwoodhotels.com/fourpoints/property/overview/index.html?propertyID=232/ Alternatively, you can see a list of nearby hotels by clicking here.

(Please note that we do not authorise any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than me regarding your accommodation requirements for this event, please let me know immediately)

View on Map
Image Gallery